FORM 4	ŀ
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person LOBELL J JAY		2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) C/O FORTRESS BIOTECH, INC., GANSEVOORT STREET, 9TH FI	. 2	3. Date of Earliest Transaction (Month/Day/Year) 01/01/2017				ther (specify bel	low)			
(Street) NEW YORK, NY 10014		4. If Amendment, D	Date Origina	ll File	ed(Month/Day	/Year)		6. Individual or Joint/Group Filing(C _X_Form filed by One Reporting Person Form filed by More than One Reporting Person		Line)
(City) (State)	(Zip)	Ta	ble I - Nor	-Der	ivative Sec	urities	Acqu	ired, Disposed of, or Beneficially O	wned	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	3. Transact Code (Instr. 8)	tion	4. Securiti (A) or Dis (Instr. 3, 4	posed o	f (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form:	7. Nature of Indirect Beneficial
		(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock, par value \$0.001	01/01/2017		А		100,000 (1)	А	\$ 0	686,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of 2. 3. Transaction 3A. Deemed 4. 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Num		
	ber of 10.	11. Nature
Derivative Conversion Date Execution Date, if Transaction of Expiration Date Amount of Derivative Derivative	tive Ownership	of Indirect
Security or Exercise (Month/Day/Year) any Code Derivative (Month/Day/Year) Underlying Security Security	ies Form of	Beneficial
(Instr. 3) Price of (Month/Day/Year) (Instr. 8) Securities Securities (Instr. 5) Benefic	cially Derivative	Ownership
Derivative Acquired (Instr. 3 and 4) Owned	Security:	(Instr. 4)
Security (A) or Follow	ing Direct (D)	
Disposed Report	ed or Indirect	
	ction(s) (I)	
(Instr. 3, (Instr. 4	4) (Instr. 4)	
4, and 5)		
Amount		
Date Expiration or		
Exercisable Date Title Number		
IO		
Code V (A) (D) Shares		
Options Options		
to purchase \$ 1.37 (2) 10/05/2020 Common Stock 25,0000000000	000 D	
Common Stock 25,0000 25,0000 25,000 25,000 25,000 25,000 25,000 25,000 2	000 D	
Stock		
Options Options		
to		
purchase \$ 6.25 (3) 02/10/2022 Common 15,000 15,000 15,000	000 D	
Common	000 D	
Stock		
Options Options		
to the second		
purchase 37.42 (4) $02/07/2023$ Common 15,000 15,00 15,000	000 D	
Stock 10,000 Stock		
Common		
Stock		
Options Options		
nurchase \$ 2.10 (5) 12/19/2023 Common 30.000 30.000	000 D	
Common		
Stock		

Reporting Owners

	Relationships			
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
LOBELL J JAY C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR	х			

NUTRIN	VODV	3137	1001
NEW	TOKK,	INY	1001

Signatures

/s/ S. Halle Vakani, Attorney-in-Fact

01/24/2017
Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) One-third of the shares will vest on each of January 1, 2018, 2019 and 2020, and subject to continued service on the board of directors.

(2) One-third of the shares vested on October 5, 2011, 2012 and 2013.

(3) One-third of the shares vested on each of February 10, 2013, 2014 and 2015.

(4) One-third of the shares vested on each of February 7, 2014, 2015 and 2016.

(5) One-third of the shares vested on each of December 19, 2014, 2015 and 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.